CONGRESS: 22–25 SEPTEMBER 2025
Congress in microcosm: more examples of learning linked to the laboratory
Next month the biennial IBMS Congress will return to the ICC in Birmingham, showcasing the very best that biomedical science and those supporting the event have to offer. In this issue, Pathology in Practice focuses on a further selection of scientific programme abstracts, alphabetically from immunology to virology.
An investment in learning and development sums up Congress exactly. Change continues to happen in pathology at an almost unprecedented pace, and this is a challenge for those needing to broaden their skills and knowledge. This is where Congress ticks so many boxes. Over four days there will be over 300 lectures across 15 different subjects and specialties. The following provides a further glimpse of what’s on the scientific programme.
Functional plasma kallikrein assay as a diagnostic tool for
bradykinin-mediated angioedema Ellie Gerred
East & South East London NHS Pathology, Barts Health NHS Trust
As an overview of hereditary
angioedema (HAE) and its classifications, the lecture will provide an in-depth understanding of HAE, including the various clinical classifications of the
disease. Specific focus will be given to HAE with normal C1 esterase inhibitor (HAE-nC1-INH), a subtype characterised by normal C1-INH levels. Recent discoveries of genetic mutations associated with HAE-nC1- INH will be introduced, expanding the understanding of its underlying molecular mechanisms. Emerging biomarkers in HAE will be
A comprehensive commercial exhibition supports the four-day programme of lectures, seminars, workshops and other events.
WWW.PATHOLOGYINPRACTICE.COM AUGUST 2025
introduced providing an insight into ongoing research aimed at identifying novel biomarkers involved in HAE pathophysiology. This will focus on how these biomarkers could be used to improve HAE diagnosis and patient management, particularly in cases of HAE-nC1-INH where traditional diagnostic markers (such as C1-INH levels) are inconclusive. Also explored will be the role of plasma kallikrein in the contact system pathway and how its dysregulation contributes to the pathophysiology of HAE. The interaction between plasma kallikrein and other components of the bradykinin pathway will be discussed and the audience will learn how this relates to the clinical manifestations of HAE The presentation will also cover the potential use of a plasma kallikrein assay as a diagnostic biomarker for HAE-nC1- INH, and a proposed methodology for measuring activated plasma kallikrein. Patient data from this proposed assay, comparing different types of HAE will
35
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
